These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 14963492

  • 1. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Zhang ZW, Guo YL.
    Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
    [Abstract] [Full Text] [Related]

  • 2. Cloning and molecular dissection of the 8.8 kb pig uroplakin II promoter using transgenic mice and RT4 cells.
    Kwon DN, Choi YJ, Park JY, Cho SK, Kim MO, Lee HT, Kim JH.
    J Cell Biochem; 2006 Oct 01; 99(2):462-77. PubMed ID: 16619260
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
    Wang D, Wang Z, Tian J, He X, Chowdhury WH, Zhang X, Li S, Rodriguez R.
    Urol Oncol; 2010 Oct 01; 28(2):164-9. PubMed ID: 18440837
    [Abstract] [Full Text] [Related]

  • 5. [Effect of mouse uroplakin II promoter on human bladder cancer cell line].
    Zhu HJ, Zhang ZQ, Zeng XF, Wei SS, Xu CX, Huang GJ, Guo YL.
    Zhonghua Zhong Liu Za Zhi; 2004 Jan 01; 26(1):22-5. PubMed ID: 15059347
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S, Kawabata M, Gotoh A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4342-8. PubMed ID: 15240520
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC, Nie MM, Yang JM, Su CQ, Sun LC, Qian YZ, Sham J, Fang GE, Wu MC, Qian QJ.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):943-8. PubMed ID: 15329284
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
    Zang Z, Mahendran R, Wu Q, Yong T, Esuvaranathan K.
    Int J Mol Med; 2004 Oct 02; 14(4):713-7. PubMed ID: 15375606
    [Abstract] [Full Text] [Related]

  • 11. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
    Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA.
    Urology; 2004 Mar 02; 63(3):613-8. PubMed ID: 15028478
    [Abstract] [Full Text] [Related]

  • 12. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Sep 02; 117(1):45-54. PubMed ID: 18791823
    [Abstract] [Full Text] [Related]

  • 13. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.
    Gene Ther; 2006 Feb 02; 13(4):330-8. PubMed ID: 16195699
    [Abstract] [Full Text] [Related]

  • 14. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
    Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC, Fang B.
    Clin Cancer Res; 2004 May 15; 10(10):3535-41. PubMed ID: 15161713
    [Abstract] [Full Text] [Related]

  • 15. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells.
    Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM.
    Mol Ther; 2004 Oct 15; 10(4):758-67. PubMed ID: 15451460
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A.
    Cancer Res; 2001 Jun 01; 61(11):4405-13. PubMed ID: 11389068
    [Abstract] [Full Text] [Related]

  • 18. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
    Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 2004 Apr 01; 11(4):256-62. PubMed ID: 15017380
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM, Korja S, Venhoranta H, Hakkarainen T, Pirinen E, Heikkinen S, Pellinen R, Mäkinen K, Wahlfors J.
    Int J Mol Med; 2006 Nov 01; 18(5):901-8. PubMed ID: 17016620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.